To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.
Signed written informed consent and volunteered to participate in the study;
Age 18-75 years old (including the cut-off value), male or female;
Locally advanced rectal adenocarcinoma confirmed by histopathology;
Clinical tumor (cT) stage cT4a or cT4b (according to the AJCC, 8th edition)
Previous allergic history to any anti-angiogenesis targeted drug, any component of monoclonal antibody, capecitabine, oxaliplatin, or other platinum drugs;
being treated with an immunosuppressive drug, or systemic hormone, for immunosuppression within 2 weeks before the first dose of the study drug (dose> 10mg/ day prednisone or equivalent); Inhaled or topical steroid use and dosage are allowed in the absence of active autoimmune disease; Prednisone 10mg/ day or equivalent dose of adrenocortical hormone replacement;
received live attenuated vaccine within 4 weeks before the first dose of study drug;
major surgery or severe trauma within 4 weeks before the first dose of study drug;
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead sponsor
Renmin Hospital of Wuhan University
Collaborator